Plain-English translation of NCT03936153 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to see if it can treat a type of aggressive lymphoma (a blood cancer) that has either come back or stopped responding to standard chemotherapy. The medication works by changing how cancer cells behave at a genetic level. Researchers want to learn whether this treatment is safe and effective for people in your situation.
People with aggressive lymphoma that doesn't respond to standard treatments have very limited options, and many don't survive long without new approaches. This trial exists to see whether this medication could offer hope to patients who have already tried two rounds of standard therapy without success.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth twice daily at a dose of 80 mg. The study takes place at multiple medical centers, and you would have regular visits to check how well the treatment is working, monitor for side effects, and have blood tests and imaging scans. The exact length and schedule of visits will be explained by the research team, but you should expect ongoing monitoring to ensure your safety and to measure whether your lymphoma is responding to treatment.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China